NCT04358055已完成不适用
Open-label, Multicenter, Prospective Investigation to Evaluate the Clinical Safety and Effectiveness of WET® Gel, Containing Hydeal-D®, an Ester of Hyaluronic Acid, in the Treatment of Nasal Dryness
Fidia Farmaceutici s.p.a.5 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2020年1月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 58
- 试验地点
- 5
- 主要终点
- General safety and tolerability of WET® gel
研究概览
简要总结
The objective of the investigation is to assess the clinical safety and effectiveness of WET® gel in the treatment of nasal dryness, following maximum two weeks of treatment.
详细描述
The objective of the project is to perform a post marketing clinical study to confirm safety and clinical effectiveness of WET® gel in the treatment of nasal dryness.
This investigation will be carried out following the CE marking of the WET® gel device and is mainly intended to answer questions relating to clinical safety or performance (i.e. residual risks) of the device when used in accordance whit its approved labelling.
The study is also aimed at defining the optimal dose regimen of WET® gel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients having undergone the informed consent process and having signed an approved consent form;
- •Male and female outpatients, aged ≥ 18 years;
- •Patients with nasal dryness of moderate-severe intensity, defined as a score ≥ 4 in a 0-10 numeric rating scale (NRS), with or without superficial microlesions;
- •Patients with absence of nasal discharge;
- •Patients having not taken oral or intranasal decongestants, antihistamines (by any route), corticosteroids (by any route), intranasal anticholinergics, leukotriene inhibitors, mucolytics (by any route), sodium cromoglycate (by any route) in the 4 weeks preceding the screening/baseline visit and agree not to take them during the investigation;
- •Patients with a cooperative attitude and ability to be trained to use correctly the investigational medical device, to adhere to the dosing and visit schedules, and agree to record symptoms' severity scores and use of the investigational device in a daily diary;
- •If female of child-bearing potential, they must have a negative urine pregnancy test at the screening visit and use a reliable form of contraception for a least 1 month prior to Screening and throughout the investigation. Note: to be considered females of non-child-bearing potential, females must be surgically sterile or postmenopausal as documented in medical history for at least 1 year.
排除标准
- •Patients with atopic or non-atopic rhinosinusitis in active phase;
- •Patients with anatomical abnormalities of the nose (turbinate hypertrophy, septal deviation, polyps) that would interfere with nasal airflow;
- •Patients with a medical history of nasal or sinus surgery in the previous 12 months;
- •Patients with upper respiratory tract or sinus infection;
- •Patients with rhinitis medicamentosa;
- •Patients with epistaxis;
- •Patients having received treatment with oral or intranasal decongestants, anti-histamines (by any route), corticosteroids (by any route), intranasal anticholinergics, leukotriene inhibitors, mucolytics (by any route), sodium cromoglycate (by any route) in the 4 weeks preceding the screening/baseline visit;
- •Patients having received treatment with antibiotics (by any route) in the 4 weeks preceding the screening/baseline visit;
- •Patients currently undergoing a progressive course of immunotherapy(hyposensitization);
- •Patients having performed a sinus lavage in the 2 weeks preceding the screening/baseline visit;
- •Patients with known or suspected allergy, hypersensitivity or intolerance to hyaluronic acid and/or any other component of the investigational device;
- •Patients with presence of any of the following clinical conditions: active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, systemic viral infections or ocular herpes simplex;
- •Patients with presence of other serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, or neurological disease that could interfere with the outcome of the investigation or the patient's ability to comply with investigation requirements;
- •Patients who have been diagnosed of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas);
- •Pregnant (positive urine test) or breastfeeding women, or planning to become pregnant during the investigation;
- •Patients with history of alcoholism or drug dependence;
- •Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the investigation;
- •Patients who have used any investigational drug or device, or have participated in an investigational protocol in the past 3 months;
- •Patients who have been previously enrolled in this investigation.
结局指标
主要结局
General safety and tolerability of WET® gel
时间窗: 15 days (the entire study duration)
The primary objective of the investigation is to evaluate the general safety and local tolerability of WET® gel in the primary endpoint incidence of treatment-related treatment-emergent adverse events (TEAEs). Endpoint: Incidence of local and general treatment-related TEAEs during the entire investigation duration.
次要结局
- Change in nasal dryness(15 days (the entire study duration))
- Percentage of patients with resolution of nasal dryness(15 days (the entire study duration))
- Time to resolution of nasal dryness(15 days (the entire study duration))
- Changes from baseline of nasal itching(15 days (the entire study duration))
- Changes from baseline of nasal crusting(15 days (the entire study duration))
- Changes from baseline of nasal burning(15 days (the entire study duration))
- Changes from baseline of nasal obstruction(15 days (the entire study duration))
- Compliance to treatment with WET® gel(15 days (the entire study duration))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
不适用
Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of CareWound Chronic DrainingNCT02138994Next Science TM43
已完成
2 期
Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)Uterine Cervical NeoplasiaCervix Intraepithelial NeoplasiaNCT01303328Mithra Pharmaceuticals200
尚未招募
1 期
Safety and Efficacy of Stem Cells for Diabetic Foot UlcerDiabetic Foot UlcerNCT06231771Supergenics Life Science Sdn. Bhd.22
已完成
1 期
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.Verruca VulgarisCommon WartsNCT02748902Neal D. Bhatia, MD16
已完成
1 期
NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone GelContraceptionNCT00229593University of Washington140